Sep 26, 2025 | Clinical case

Compare your opinion with peers and Prof. Jørgen Bjerggaard Jensen

Peter, a 72-year-old retired engineer, was diagnosed with T1 high-grade (HG) non-muscle-invasive bladder cancer (NMIBC) 18 months ago. Following a successful transurethral resection of the bladder tumour (TURBT) and re-TURBT without further pathology, he received a full induction course of bacillus Calmette-Guérin (BCG) therapy followed by maintenance BCG.

At his initial 3-month follow-up cystoscopy, he was confirmed disease-free. According to standard guidelines for high-risk NMIBC, Peter’s surveillance schedule involves frequent cystoscopies and urinary cytology every 3 months for the first 2 years.

During his next follow-up visit, Peter raises that these frequent, invasive cystoscopies cause him significant anxiety well ahead of each appointment. The continuous need for hospital visits also disrupts his otherwise active retirement, adding a considerable burden to his daily life. Moreover, he experienced a urinary tract infection (UTI) following last cystoscopy leading to delay of maintenance BCG instillation.

Cast your vote and see what Prof. Prof. Jørgen Bjerggaard recommends for this patient case!

A
B
C

Continue with routine, frequent cystoscopies

Alternate urinary biomarker with cystoscopy; performing an earlier cystoscopy only if the urinary test yields a positive or unconclusive result

Discontinue all regular surveillance visits, relying solely on symptom-driven investigations for recurrence

Other updates

Urinary biomarkers for the surveillance of NMIBC

Can urinary biomarkers help address some of the key limitations of cystoscopy and urine cytology in the surveillance of non-muscle-invasive bladder cancer (NMIBC)? Watch this expert presentation to discover how urinary biomarkers may support a more patient-centred and...

read more